Dr. Christophe Arbet-Engels talks about some of the diabetes drugs in Boehringer Ingelheim’s pipeline including several compounds with liagliptin which BI is continuing to study and expand their knowledge of. They have looked at data in the past on African Americans and are now examining data of the drug’s efficacy in …
Read More »Christophe Arbet-Engels, MD, Q6: SGLT-2 Safety Profile
Dr. Christophe Arbet-Engels talks about the empagliflozin studies and the ongoing safety program to identify any safety and side-effect concerns. However, despite reported potential urinary tract and genital infection issues, the large majority of patients of the study's 14,000 participants didn't observe any of these effects.
Read More »Christophe Arbet-Engels, MD, Q7: How Does Empagliflozin Differ from Other SGLT-2 Inhibitors?
Dr. Christophe Arbet-Engels talks about how empagliflozin differs from other SGLT-2 inhibitors already on the market such as canagliflozin and dapagliflozin, stating that empagliflozin is “very specific” to its target, but hasn’t yet been compared to the others so it is too early to tell what other differences there might be. …
Read More »Christophe Arbet-Engels, MD, Q3: Cooperation between Boehringer and Lilly
Dr. Christophe Arbet-Engels explains how Eli Lilly and Boehringer Ingelheim have created and alliance and what that means in terms of promotion. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources
Read More »FDA Warning: Invokana Can Increase Risk of Bone Fracture
Bone mineral density at hip and lower spine may also decrease.
Read More »Effects of Diabetes Medications on Heart Complications
Reduced risk of heart attacks, strokes, cardiovascular events suggested.
Read More »Discussion of Practical Implementation of SGLT-2’s with a Patient, Part 3
In this week’s Homerun Slides, we continue our short series on introducing SGLT-2 inhibitor therapy to your patients. Topics this week include: Practical Clinical Approaches To Maximize Benefits and Minimize Risks… To download the complete set in PowerPoint format, just use this link: Discussion of Practical Implementation of SGLT-2’s with a Patient, …
Read More »Discussion of Practical Implementation of SGLT-2’s with a Patient, Part 2
In this week’s Homerun Slides, we continue our short series on introducing SGLT-2 inhibitor therapy to your patients. Topics this week include: Logic for SGLT-2 Inhibition, But Won’t Sugar Hurt My Kidneys, and CV Risk factor Changes with SGLT-2 Inhibitors…
Read More »Discussion of Practical Implementation of SGLT-2’s with a Patient, Part 1
A short series, courtesy Dr. Stanley Schwartz, on discussing SGLT-2 inhibitor therapy with your patients
Read More »Can an SGLT-2 Inhibitor Be Used in Type 1 Diabetes?
SGLT-2 inhibitors are a new class of drug for the treatment of type 2 diabetes, but they are also being used off label in patients with type 1 diabetes.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.